tbuckley/cabot-search huggingface dataset:
Abstract 20147: Relation Between Preoperative Endothelial Dysfunction and Adverse Events After Cardiovascular Surgery
Authors: Yuichi Saito, Hideki Kitahara, Goro Matsumiya, Yoshio Kobayashi
Journal: Circulation (2017)

Introduction: Cardiovascular surgery is one of the highest risk procedures in the field of surgery. Hypothesis: Preoperative assessment of endothelial function has been reported to be useful for pr...
Changes in Prevalence of Marijuana Consumption Modes Among Colorado High School Students From 2015 to 2017
Authors: Kayla N. Tormohlen, Kristin E. Schneider, Renee M. Johnson, Ming Ma, Arnold H. Levinson, Ashley Brooks-Russell
Journal: JAMA Pediatrics (2019)

Smoking is the most prevalent mode of marijuana consumption among adolescents, but nonsmoking modes, including ingesting, vaporizing, and dabbing, have expanded in the context of legalization. 1,2Each mode of consumption has different effects that may be associated with distinct health consequences. 3Previous research in Colorado identified smoking as the most commonly used mode of marijuana consumption among high school students and found that the prevalence of primarily ingesting marijuana declined after the implementation of retail marijuana sales. 4We examined changes in modes of marijuana consumption among high school students in Colorado from 2015 to 2017.Methods | Data came from the 2015 and 2017 administrations of the Healthy Kids Colorado Survey (HKCS), a biennial crosssectional survey conducted in Colorado public schools. 5The HKCS uses a 2-stage stratified cluster design with random sampling of public middle/high schools and of classrooms within schools.This study includes 9th-through 12th-grade students who reported using marijuana in the past 30 days (1664 in 2015; 3618 in 2017).The Colorado Multiple institutional review board approved the data collection.Teachers provided instructions that stated that students could choose to skip questions or not participate without consequence.
Gram-Negative Pneumonia Augments Non–Small Cell Lung Cancer Metastasis through Host Toll-like Receptor 4 Activation
Authors: Stephen D. Gowing, Simon C. Chow, Jonathan J. Cools-Lartigue, Crystal B. Chen, Sara Najmeh, Marnie Goodwin-Wilson, Henry Y. Jiang, France Bourdeau, Annie Beauchamp, Isabelle Angers, Betty Giannias, Jonathan D. Spicer, Simon Rousseau, Salman T. Qureshi, Lorenzo E. Ferri
Journal: Journal of Thoracic Oncology (2019)

IntroductionSurgery is essential for cure of early-stage non-small cell lung cancer (NSCLC). Rates of postoperative bacterial pneumonias, however, remain high, and clinical data suggests that post-operative infectious complications confer an increased risk for metastasis. Toll-like receptors (TLRs) mediate the inflammatory response to infection by recognizing evolutionarily conserved bacterial structures at the surface of numerous pulmonary cell types; yet, little is known about how host TLR activation influences NSCLC metastasis. TLR4 recognizes gram-negative bacterium lipopolysaccharide activating the innate immune system.MethodsC57BL/6 and TLR4 knockout murine airways were inoculated with Escherichia coli or lipopolysaccharide. Hepatic metastasis assays and intravital microscopy were performed. Bronchoepithelial conditioned media was generated through coincubation of bronchoepithelial cells with TLR4 activating Escherichia coli or lipopolysaccharide. Subsequently, H59 NSCLC were stimulated with conditioned media and subject to various adhesion assays.ResultsWe demonstrate that gram-negative Escherichia coli pneumonia augments the formation of murine H59 NSCLC liver metastases in C57BL/6 mice through TLR4 activation. Additionally, infected C57BL/6 mice demonstrate increased H59 NSCLC in vivo hepatic sinusoidal adhesion compared with negative controls, a response that is significantly diminished in TLR4 knockout mice. Similarly, intratracheal injection of purified TLR4 activating lipopolysaccharide increases in vivo adhesion of H59 cells to murine hepatic sinusoids. Furthermore, H59 cells incubated with bronchoepithelial conditioned medium show increased cell adhesion to in vitro extracellular matrix proteins and in vivo hepatic sinusoids through a mechanism dependent on bronchoepithelial TLR4 activation and interleukin-6 secretion.ConclusionTLR4 is a viable therapeutic target for NSCLC metastasis augmented by gram-negative pneumonia.
Challenges to Realizing Benefits From More Intensive Blood Pressure Control for Preventing Recurrent Stroke
Authors: Craig S. Anderson
Journal: JAMA Neurology (2019)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Neurology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Neurology journal
Prognostic factors in Chinese patients with chronic lymphocytic leukemia
Authors: W. XU, J. Li, S. Zhang, Y. Wu, Y. Zhu, Y. Zhu
Journal: Journal of Clinical Oncology (2007)

17518 Background: Recently, some new factors, such as cytogenetic abnormalities, ZAP-70, proliferative antigen Ki-67, and the expression of CD38 in leukaemic cells, were strong indicator of prognosis in B-cell chronic lymphocytic leukaemia (B-CLL). The aim of this study was to explore the characteristics of molecular cytogenetics in Chinese patients with CLL, evaluate the expression of Ki-67, ZAP-70 and CD38 in leukaemic cells, and analyze the influence of factors on the prognosis of CLL. Methods: Interphase fluorescence in situ hybridization (FISH) was used to detect cytogenetic aberrations, and a panel of FISH probes for 13q14 (D13S319), 17p13 (p53 gene), 11q23 (ATM gene), the centromere of chromosome 12 (D12Z3) and 14q32 (IGHC/IGHV) was applied on bone marrow or peripheral blood smears from 52 Chinese B-CLL patients; Four-color flow cytometry was used to determined the expression of ZAP-70 protein and CD38; Immunohistochemistry was applied to measure the expression of Ki-67 antigen and Bcl-2 protein. Kaplan-Meier was used for survival time. Results: Out of the 52 patients, 42 (80.7%) had at least one kind of molecular cytogenetic aberration and 16 (30.8%) with 2 abnormalities. The most frequent abnormalities detected in our patients was deletions of 13q14 in 26 cases (50.0%), followed by trisomy of chromosome 12 in 11 patients (21.2%), deletions of 17p13 in 10 patients (19.2%), deletions of 11q23 in 6 patients (11.5%), and 14q32 translocation in 5 patients (9.6%). Fourteen patients (26.9%) were positive for ZAP-70 (=20%), and 13 patients (25.0%) were positive for CD38. Positive ZAP-70 and CD38 status was associated with advanced disease stage (Binet C). The expression levels of Ki-67 in Binet C stage was higher than that in early stage (Binet A and B). In univariate analysis for survival, 13q14 deletion was a favorable prognostic factor, and the deletions of 17p13 and 11q23 were poor prognostic factors. The survival time was longer in the group with lower expression of Ki-67 than that in the higher expression group. Both ZAP-70 and CD38 expression were shown to predict the clinical course of the disease. Conclusions: Chromosomal aberrations (deletions of 13q14, 17p13 and 11q23), and expression of Ki-67, ZAP-70 and CD38 have been shown highly predictive prognostic value for Chinese patients with B-CLL. No significant financial relationships to disclose.
Prevalence of symptom clusters among sarcoma patients in active treatment.
Authors: Vanessa C. Copeland, Jennifer Phun, Eve M. Segal, Kathryn J. Hammer, Elizabeth T. Loggers
Journal: Journal of Clinical Oncology (2019)

e22561 Background: Cancer patients (pt) frequently experience symptoms from cancer or its treatment. Two or three co-occurring, uncontrolled symptoms (symptom clusters, SC), can worsen cancer pt morbidity and mortality. Although SC have been characterized in other cancer pts, little research has been conducted in sarcoma pts. Methods: SC were studied via retrospective chart review of adult sarcoma pts receiving treatment between 09/2018-01/2019 in a dedicated sarcoma clinic. Pts completed a 33-item, modified Patient Reported Outcomes-Common Terminology Criteria for Adverse Events (mPRO-CTCAE)-based review of systems (hereafter “form”) for ongoing clinical care with presence of individual symptoms defined as ≥“occasionally.” Demographic, disease and treatment specific data was collected; descriptive data (%’s) are presented. Results: Pts (n = 153 completing 321 forms) were median 57 years (range 20-81), 48% male, 68% white, with lower extremity (29%) or abdomen (46%) sarcoma with 67% receiving IV chemo (33% oral chemo), with the majority at full dose (77%). Most had leiomyosarcoma 18%, liposarcoma 14%, GIST 12%, or NOS 24% with 59% metastatic disease. Five SC triads occurring in &gt; 25% of pts who fully completed one form were identified (see Table). Eighty-one pts completed 2 or more forms (mean 26.7 days from first to second form [std dev 17.7, range 2-77]) with 50-67% of evaluable pts having ongoing SC triads. Conclusions: Symptom clusters are common among sarcoma patients on active treatment. Future research should address optimal management of these clusters. Additional data, including severity/interference of symptoms, longitudinal changes and predictors of SC, will be presented.[Table: see text]
Oral morphine gargles: A cost effective approach for pain relief in patients with chemoradiation induced acute oral mucositis in head and neck cancers
Authors: C. Haritha, V. Shankar
Journal: Journal of Clinical Oncology (2009)

e20504 Background: Painful oral mucositis is the most significant dose-limiting toxicity in head &amp; neck cancer patients treated with conc. CT-RT protocol. The purpose of this study is to evaluate the efficacy of oral morphine gargles in reducing the severity of chemoradiation induced mucositis pain &amp; thus, its impact on nutrition, quality of life &amp; cost of supportive care, during the treatment period. Methods: 106 consecutive patients, recruited between May 2006 through Dec. 2007, with adv. head and neck cancers (54 oropharynx, 42 hypopharynx &amp; 10 nasopharynx) were included in the study. All patients underwent treatment under conc. CT-RT (Inj.CDDP 40mg/m 2 weekly, RT: 66–70gy/33–35# @200cgy/# delivered by 3D- CRT). Patients who had painful mucositis (RTOG Grade 3 or more) not controlled with magic mouthwash, Tab. Acetaminophen 500mg qds or Tab.Tramdol 50–100 mg tds were randomized into 2 groups: morphine group (MOP) -53 patients &amp; Control group (CON) - 53 patients. Patients in both groups received adjusted doses of oral steroids based on the severity of oral mucositis. While CON group patients were given adjusted doses of tramadol, MOP group patients were assigned to 15ml of 2% morphine gargles administered every 4th hourly. Patients were instructed not to swallow the rinses and to hold the solution in the mouth for 3mins duration. All patients underwent weekly recording of (1) response to pain rated on VAS (2) weight (3) morphine systemic side-effects (4) QOL Questionnaire. Mann-Whitney test and ’T’ Test are used for statistical analysis of the data. Results: Patients in the MOP group had significant lower pain intensity scores, better QOL scores &amp; less weight loss compared to patients in the CON group. The duration of the severe pain was atleast 1 week shorter in the MOP group. Systemic side-effects secondary (nausea, vomiting, constipation) to opiod use were significantly lower in the MOP group. The Cost of supportive care for pain management was less in the MOP group, with greater compliance for the treatment. Conclusions: Morphine gargles, in our experience, is an effective approach for pain relief in patients with CT-RT induced acute mucositis in head and neck cancers thus leading to better nutrition &amp; compliance in the treatment. No significant financial relationships to disclose.
MR-guided laser-induced thermotherapy (LITT) in liver metastases of colorectal cancer: Long-term survival data.
Authors: Thomas J. Vogl, Alena Dommermuth, Katrin Eichler, Stephan Zangos
Journal: Journal of Clinical Oncology (2012)

e14131 Background: To evaluate retrospectively long-term survival of 594 patients with colorectal liver metastases treated with MR-guided laser-induced thermotherapy (LITT) depending on different factors. Methods: 594 patients with liver metastases from colorectal carcinoma treated with MR-guided LITT between 01/99 and 12/10 were included. For survival analysis tumor localization, TNM classification, number of metastases, diameter and volume of metastases and necrosis, lobular spread, number of treatment sessions, performance of adjuvant chemotherapy and transarterial chemoembolisation were considered. The Kaplan-Meier method was used to conduct this survival analysis. Results: Log-rank test showed statistically significant differences between survival curves, multivariate Cox-regression-analysis (p&lt;0.05) showed prognostic factors regarding overall survival like number of metastases pre intervention, adjuvant chemotherapy, diameter of metastases, ratio of volumes of necrosis and metastases, and affected lymph nodes. Median overall survival rate at the time of first LITT was 25 months, 1-year survival: 78%, 2-year survival: 50.1%, 3-year survival: 28%; 4-year survival: 16.4%; 5-year survival: 7.8%. Numbers of metastases pre intervention: 1-2 metastases with a median survival rate of 60 months; 3-4 metastases: 45 months; ≥5 metastases: 42 months. Median survival rate for metastases &lt;20mm in diameter 36 months; 20-30mm 27 months, 30-40mm 24 months and &gt;40mm 21 months. Affected lymph nodes: median survival rate for patients with N0-classification 30 months, N1-classification 24 months; N2/N3/N4-classification 22 months. Conclusions: Multivariate Cox regression model provided the minimal number of significant variables with the maximal prognostic value concerning overall survival for MR-guided LITT, i.e., diameter and number of metastases and primary classification of lymph nodes.
5-Aminolevulinic photodynamic therapy versus carbon dioxide laser therapy for small genital warts: A multicenter, randomized, open-label trial
Authors: Ping Tu, Haiyan Zhang, Heyi Zheng, Heng Gu, Jinhua Xu, Jining Tao, Hongwei Wang, Xuejun Zhu, Xiuli Wang
Journal: Journal of the American Academy of Dermatology (2019)
Close encounters of the US kind: illness and injury among US athletes at the PyeongChang 2018 Winter Olympic Games
Authors: Dustin Nabhan, Johann Windt, David Taylor, William Moreau
Journal: British Journal of Sports Medicine (2019)

Aim To describe injury and illness incidence during the 2018 Winter Olympic Games (WOG) by Team USA. Methods A descriptive observational study. We used registered Team USA Olympic athletes’ electronic medical records to review preparticipation health histories and medical encounters immediately prior to and throughout the 2018 WOG. Medical encounters were defined as all medical services provided by a healthcare provider, including evaluation, treatment and prophylactic services. All medical conditions were described according to International Olympic Committee injury and illness reporting criteria. Results Team USA included 134 men and 108 women, aged 18–39 years, who represented 17 sport federations. The 47 Team USA medical staff documented 1744 medical encounters on 242 registered athletes (7.2 medical encounters per athlete). Forty-seven illnesses (194.2/1000 athletes) and 32 time loss injuries (132.2/1000 athletes) were recorded during the Games. Conclusions An injury surveillance programme consisting of an electronic preparticipation health history and surveillance of medical encounters during the WOG was used to describe the health status of Team USA. We noted limitations to the surveillance process that can be addressed at future events.
Inter‐ and intrarater reliability of Hurley staging
Authors: Z.N. Ovadja, M.M. Schuit, C.M.A.M. Horst, O. Lapid
Journal: British Journal of Dermatology (2019)

Staging disease when the patient comes for their consultation is an important part of estimating the disease's subsequent course (prognosis) and the likely effectiveness of any treatment. Staging means formally assessing the disease's severity including its extent, such as how much of the skin is affected. Hidradenitis suppurativa (HS) is a chronic skin inflammation in the body folds, such as the groin or armpit areas, in which large boils and pustules form, which can cause scarring. There are at least 4 different scoring methods in use to stage the disease, the most popular of which is known as the Hurley staging scheme. This study, which was an international co‐operation between departments in Germany, Denmark and Poland, was designed to check the agreement between different dermatologists, including those in training, on their rating of the stage of HS in 5 different patients on two separate occasions. The exercise showed how difficult it is to obtain consistent assessments both between different physicians and with the same physician on separate occasions. The scoring method, in which there was the highest level of agreement, both between different doctors or by the same doctor on different occasions was the one known as the International Hidradenitis Suppurative Scoring System as well as the HS physicians Global Assessment scale. The authors emphasise the importance of training doctors on how to use of these scoring systems in order to maximise their benefits.
Blood-based biomarkers for detecting aggressive prostate cancer at time of biopsy
Authors: R. K. Nam, K. W. Marshall, R. Zheng, H. W. Zhang, S. A. Narod, C. C. Liew
Journal: Journal of Clinical Oncology (2006)

4637 Background: To date, we have applied our unique methodology (the Sentinel Principle) to identify blood-based gene expressed biomarkers for several diseases including osteoarthritis, bladder cancer and psychiatric disorders. It is well known that new biomarkers for prostate cancer detection are needed, particularly aggressive forms of prostate cancer. Our objective was to identify gene expression signatures and to characterize a set of biomarkers from whole blood to identify patients with aggressive forms of prostate cancer at the time of prostate biopsy. Methods: We conducted a two staged study. The first stage was for gene discovery using microarrays (Affymetrix U133Plus2.0 GeneChips) among 47 patients (all Caucasian) who underwent a prostate biopsy for prostate cancer. We included 16 patients (cases) diagnosed with aggressive forms of prostate cancer defined as having a histologic grade of Gleason Score 7 or more and 31 patients with no evidence of cancer at biopsy (controls). The second stage was a validation study (108 patients) using real-time RT-PCR methods. Logistic regression was used to assess the ability of linear combinations of specific transcripts to distinguish cancers from controls. Results: In the first stage, we identified 1661 probes that were significantly different in blood gene expression profiles between cases and controls (p&lt;0.05). In the second stage, real-time RT-PCR assays validated four genes among 33 cases and 75 controls: three up-regulated genes: A 1.4 fold, p&lt;0.001, B 1.2 fold, p=0.03, C 1.3 fold, p=0.08; and one down-regulated gene D 0.70, p=0.008. Linear combination of these 4 genes discriminated the cases from controls with a sensitivity of 90% and specificity of 53% (AUC: 0.80, 95% C.I.: 0.713∼0.871). The performance of PSA (4 ng/ml cut-off) in the same 108 sample set was 91% sensitivity and 13% specificity (AUC: 0.67, 95% CI: 0.75∼0.98). The performance of combining the four blood biomarkers with PSA yielded an AUC of 0.86 (95% C.I.: 0.77∼0.91) with a sensitivity 90% and specificity 70%. Conclusions: When used with PSA, these four blood-based biomarkers improved the overall accuracy to identify patients with prostate cancer at biopsy. These results would have important implications for new biomarkers discovery for prostate cancer detection. [Table: see text]
A phase III study of standard fractionation radiotherapy with concurrent high-dose cisplatin versus accelerated fractionation radiotherapy (RT) with panitumumab in patients with locally advanced stage III and IV squamous cell carcinoma of the head and neck (SCCHN) (NCIC Clinical Trials Group HN.6).
Authors: John N Waldron, Wendy Parulekar, Brian O'Sullivan, Bingshu E Chen, Alexander Montenegro, Abdenour Nabid, Eric Winquist, Jim R. Wright, John Hay, Jolie Ringash, Rosemary Martino, Ana Johnson, Geoffrey Liu, Stephen Breen, Ralph William Gilbert, George Shenouda, Lillian L. Siu
Journal: Journal of Clinical Oncology (2012)

TPS5600 Background: Standard treatment for locally advanced SCCHN, chemoradiotherapy (CRT), leads to significant acute and long-term morbidity. The demonstration that EGFR antibody (Ab) therapy improves outcome when added to standard RT (Bonner NEJM 2006) and that altered fractionation RT improves outcome compared to standard RT that is of similar magnitude as CRT (Bourhis Lancet 2006), led to the hypothesis that the combination of the two treatment strategies will improve efficacy compared to standard CRT with good tolerability. Methods: HN.6 is a Canadian phase III randomized study comparing standard RT 70Gy/35 over 7 weeks + cisplatin 100mg/m 2 d 1, 22, 43 to accelerated RT 70Gy/35 over 6 weeks + panitumumab (anti EGFR Ab)) 9mg/kg 1 week prior to RT, d15, 36. Key eligibility criteria are: SCC of oral cavity, oropharynx, larynx or hypopharynx; TanyN+M0 or T3-4N0M0; adequate organ function and PS. Primary endpoint is progression free survival (PFS). Secondary endpoints include OS, local PFS, regional PFS, distant metastases, swallowing related QOL, functional swallowing outcomes, and economic evaluation (healthcare utilization, health utilities, indirect costs). Tissue and blood collection will allow biomarker evaluation including HPV status. Real time quality review of RT plans with plan data and radiology archiving will allow future analysis of RT parameters relative to toxicity and patterns of failure. Clinical epidemiological data will be prospectively collected and correlated with biomarkers and outcome. Planned sample size is 320 patients over 3.2 years with 3 more years of follow-up and target hazard ratio = 0.7 (absolute difference in control arm 2 year PFS of 12%, power 80%, 2-tail type 1 error 0.05). If superiority is not demonstrated, noninferiority will be tested. One interim analysis is planned. Conduct to Date: Study activation: Dec 2008 and completed accrual in Nov 2011. In Oct 2011, the DSMC recommended trial continuation. Supported by CCSRI grant 021039 and Amgen Inc. ClinicalTrials.gov: NCT00820248.